NATERA INC (NTRA) Fundamental Analysis & Valuation

NASDAQ:NTRA • US6323071042

Current stock price

196.4 USD
-10.79 (-5.21%)
Last:

This NTRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. NTRA Profitability Analysis

1.1 Basic Checks

  • In the past year NTRA has reported negative net income.
  • NTRA had a positive operating cash flow in the past year.
  • In the past 5 years NTRA always reported negative net income.
  • In multiple years NTRA reported negative operating cash flow during the last 5 years.
NTRA Yearly Net Income VS EBIT VS OCF VS FCFNTRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -8.68%, NTRA belongs to the top of the industry, outperforming 82.56% of the companies in the same industry.
  • With an excellent Return On Equity value of -12.16%, NTRA belongs to the best of the industry, outperforming 84.88% of the companies in the same industry.
Industry RankSector Rank
ROA -8.68%
ROE -12.16%
ROIC N/A
ROA(3y)-16.77%
ROA(5y)-25.55%
ROE(3y)-28.3%
ROE(5y)-46.95%
ROIC(3y)N/A
ROIC(5y)N/A
NTRA Yearly ROA, ROE, ROICNTRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

1.3 Margins

  • NTRA has a better Gross Margin (64.75%) than 78.49% of its industry peers.
  • In the last couple of years the Gross Margin of NTRA has grown nicely.
  • NTRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.42%
GM growth 5Y6.2%
NTRA Yearly Profit, Operating, Gross MarginsNTRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NTRA Health Analysis

2.1 Basic Checks

  • NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NTRA has more shares outstanding
  • The number of shares outstanding for NTRA has been increased compared to 5 years ago.
  • The debt/assets ratio for NTRA has been reduced compared to a year ago.
NTRA Yearly Shares OutstandingNTRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NTRA Yearly Total Debt VS Total AssetsNTRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • NTRA has an Altman-Z score of 25.13. This indicates that NTRA is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of NTRA (25.13) is better than 90.50% of its industry peers.
  • NTRA has a debt to FCF ratio of 1.06. This is a very positive value and a sign of high solvency as it would only need 1.06 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.06, NTRA belongs to the top of the industry, outperforming 94.19% of the companies in the same industry.
  • NTRA has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • NTRA has a Debt to Equity ratio of 0.05. This is comparable to the rest of the industry: NTRA outperforms 41.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 1.06
Altman-Z 25.13
ROIC/WACCN/A
WACC9.11%
NTRA Yearly LT Debt VS Equity VS FCFNTRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 3.39 indicates that NTRA has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.39, NTRA perfoms like the industry average, outperforming 41.86% of the companies in the same industry.
  • NTRA has a Quick Ratio of 3.24. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.24, NTRA is in line with its industry, outperforming 41.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.39
Quick Ratio 3.24
NTRA Yearly Current Assets VS Current LiabilitesNTRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NTRA Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 0.65% over the past year.
  • NTRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.90%.
  • Measured over the past years, NTRA shows a very strong growth in Revenue. The Revenue has been growing by 42.61% on average per year.
EPS 1Y (TTM)0.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%187.8%
Revenue 1Y (TTM)35.9%
Revenue growth 3Y41.14%
Revenue growth 5Y42.61%
Sales Q2Q%39.78%

3.2 Future

  • The Earnings Per Share is expected to grow by 37.27% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 17.55% on average over the next years. This is quite good.
EPS Next Y-22.95%
EPS Next 2Y28.79%
EPS Next 3Y39.13%
EPS Next 5Y37.27%
Revenue Next Year19.59%
Revenue Next 2Y19.65%
Revenue Next 3Y19.4%
Revenue Next 5Y17.55%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NTRA Yearly Revenue VS EstimatesNTRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
NTRA Yearly EPS VS EstimatesNTRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

2

4. NTRA Valuation Analysis

4.1 Price/Earnings Ratio

  • NTRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTRA Price Earnings VS Forward Price EarningsNTRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 -100

4.2 Price Multiples

  • NTRA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NTRA is cheaper than 88.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF 365.72
EV/EBITDA N/A
NTRA Per share dataNTRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • NTRA's earnings are expected to grow with 39.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.79%
EPS Next 3Y39.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NTRA Dividend Analysis

5.1 Amount

  • NTRA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NTRA Fundamentals: All Metrics, Ratios and Statistics

NATERA INC

NASDAQ:NTRA (4/16/2026, 3:32:58 PM)

196.4

-10.79 (-5.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners92.19%
Inst Owner Change0.19%
Ins Owners3.06%
Ins Owner Change1.64%
Market Cap27.84B
Revenue(TTM)2.31B
Net Income(TTM)-208.16M
Analysts85
Price Target258.63 (31.69%)
Short Float %3.56%
Short Ratio3.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)50.47%
Min EPS beat(2)-68.19%
Max EPS beat(2)169.13%
EPS beat(4)2
Avg EPS beat(4)26.55%
Min EPS beat(4)-68.19%
Max EPS beat(4)169.13%
EPS beat(8)5
Avg EPS beat(8)29.82%
EPS beat(12)8
Avg EPS beat(12)21.96%
EPS beat(16)12
Avg EPS beat(16)18.12%
Revenue beat(2)2
Avg Revenue beat(2)11.68%
Min Revenue beat(2)10.13%
Max Revenue beat(2)13.23%
Revenue beat(4)4
Avg Revenue beat(4)11.53%
Min Revenue beat(4)10.13%
Max Revenue beat(4)13.23%
Revenue beat(8)8
Avg Revenue beat(8)13.31%
Revenue beat(12)12
Avg Revenue beat(12)10.39%
Revenue beat(16)14
Avg Revenue beat(16)8.14%
PT rev (1m)-1.43%
PT rev (3m)5.75%
EPS NQ rev (1m)3.07%
EPS NQ rev (3m)2.37%
EPS NY rev (1m)1.69%
EPS NY rev (3m)2.7%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)2%
Revenue NY rev (1m)1.23%
Revenue NY rev (3m)3.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.07
P/FCF 365.72
P/OCF 129.29
P/B 16.26
P/tB 23.24
EV/EBITDA N/A
EPS(TTM)-1.52
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)0.54
FCFY0.27%
OCF(TTM)1.52
OCFY0.77%
SpS16.27
BVpS12.08
TBVpS8.45
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -8.68%
ROE -12.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.75%
FCFM 3.3%
ROA(3y)-16.77%
ROA(5y)-25.55%
ROE(3y)-28.3%
ROE(5y)-46.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.42%
GM growth 5Y6.2%
F-Score5
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 1.06
Debt/EBITDA N/A
Cap/Depr 320.09%
Cap/Sales 6.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.39
Quick Ratio 3.24
Altman-Z 25.13
F-Score5
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)243.71%
Cap/Depr(5y)291.51%
Cap/Sales(3y)4.73%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%187.8%
EPS Next Y-22.95%
EPS Next 2Y28.79%
EPS Next 3Y39.13%
EPS Next 5Y37.27%
Revenue 1Y (TTM)35.9%
Revenue growth 3Y41.14%
Revenue growth 5Y42.61%
Sales Q2Q%39.78%
Revenue Next Year19.59%
Revenue Next 2Y19.65%
Revenue Next 3Y19.4%
Revenue Next 5Y17.55%
EBIT growth 1Y-37.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.76%
EBIT Next 3Y38.7%
EBIT Next 5Y29.98%
FCF growth 1Y29.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.7%
OCF growth 3YN/A
OCF growth 5YN/A

NATERA INC / NTRA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NATERA INC (NTRA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to NTRA.


What is the valuation status of NATERA INC (NTRA) stock?

ChartMill assigns a valuation rating of 2 / 10 to NATERA INC (NTRA). This can be considered as Overvalued.


Can you provide the profitability details for NATERA INC?

NATERA INC (NTRA) has a profitability rating of 3 / 10.


What is the expected EPS growth for NATERA INC (NTRA) stock?

The Earnings per Share (EPS) of NATERA INC (NTRA) is expected to decline by -22.95% in the next year.